Clinical Trial

Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell Lymphoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of the main clinical research study is to learn if treatment with a chimeric antigen receptor (CAR) T-cell therapy called lisocabtagene maraleucel (liso-cel) can help to prevent recurrence of large B-cell cell lymphoma in patients who have achieved complete response (CR) after standard first-line therapy but have tested positive for lymphoma DNA. CAR T therapy is a type of treatment that uses your own immune cells to fight your cancer. The safety of this treatment will also be studied.
Protocol Amendment History 3 changes
critical Trial status changed: Active, Not Recruiting → Recruiting 2026-07-01
critical Recruitment suspended 2026-05-21
critical Recruitment opened 2026-05-02
Trial Details
NCT Number NCT07316010
Lead Sponsor M.D. Anderson Cancer Center
Conditions Large B-cell Lymphoma
Enrollment 50 participants
Start Date 2026-03-17
Primary Completion 2029-03-21 (estimated)
Study Completion 2031-03-21 (estimated)
Updated on ClinicalTrials.gov 2026-06-30